Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by jplordureon Oct 07, 2015 9:34am
93 Views
Post# 24170920

RE:Antibe buys a new company... Why? ATB-346 doesn't work?

RE:Antibe buys a new company... Why? ATB-346 doesn't work?Great bashing!
BeenHereBefore wrote: So Antibe acquires a new company, presumably with safe and effective products... Is that because the next news release will announce that ATB-346 failed (yet again) during the mandatory 3rd-party validation studies? 

Is Antibe working on a classic "shareholder attention redirect?" Shouldn't be too hard. Near-term shareholder memory is already corrupted, what with so many people once again pumping the greatness of a drug that poisoned people's livers and required Phase I human trials to be suspended less than nine months ago. All is quickly forgiven by underwater shareholders looking to get out of the hole they're in.

Key quote from the NR:

"We believe that these transactions will provide new avenues of growth for Antibe..." Yeah, new avenues (orthodontics? bone regeneration?) when they can no longer hide the fact that the old avenue (ATB-346) has failed.

Translation: Our much hyped product won't be coming to market but look at the shiny new company we bought! Derrrp.

The timing is right for a little subterfuge. Validation results are due by the end of the year. Maybe Antibe is preparing for the worst and hoping to soften the blow with this very "strategic" acquisition.



Bullboard Posts